
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher is well-positioned for long-term growth given its strong portfolio of scientific instruments and consumables in the life sciences and diagnostic industries. The recent divestiture of its environmental and applied solutions group, Veralto, allows the company to focus more heavily on its core businesses. The expected close of the Masimo acquisition in 2H 2026 and a broadening bioprocess recovery add to the company's growth potential. The company is actively addressing any challenges in its diagnostic business and is committed to diversity and inclusion in its leadership roles.
Bears say
Danaher is a global science and technology company focused on biotechnology, life sciences, and diagnostics, but its sustainability concerns and recent underperformance in the life science tools market are potential indicators of fundamental issues underlying the company's growth. With an extensive manufacturing footprint and potential challenges in decarbonization, coupled with recent business divestitures and acquisitions, Danaher's growth may face headwinds as it continues to integrate and evolve its business operations. As such, a negative outlook is warranted, and a downside scenario could see materialization in the form of persistent sluggishness in bioprocess equipment demand, decelerating trends in diagnostics, and challenges with future acquisition target selection.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares